The KDM6B antibody is a crucial tool in epigenetic research, targeting the lysine demethylase 6B (KDM6B), also known as JMJD3. KDM6B is a histone-modifying enzyme belonging to the KDM6 subfamily, which specifically demethylates di- and tri-methylated lysine 27 on histone H3 (H3K27me2/3). This post-translational modification is linked to transcriptional repression, and its removal by KDM6B activates gene expression, playing pivotal roles in development, cellular differentiation, and immune responses. KDM6B is implicated in regulating stem cell pluripotency, somatic cell reprogramming, and senescence.
Antibodies against KDM6B enable the detection and localization of the protein in various experimental applications, including Western blotting, chromatin immunoprecipitation (ChIP), and immunofluorescence. They are widely used to study KDM6B's involvement in diseases such as cancer, where it may act as an oncogene or tumor suppressor depending on context, and neurodevelopmental disorders. Dysregulation of KDM6B has been associated with multiple cancers (e.g., leukemia, glioblastoma), autoimmune diseases, and aging-related pathologies. Researchers also utilize these antibodies to explore its interaction with signaling pathways like Wnt and TGF-β. As an essential reagent, KDM6B antibodies advance understanding of epigenetic mechanisms and potential therapeutic targets in human health and disease.